News | November 05, 2021
Prime Therapeutics to list Semglee and Insulin Glargine
Biocon Biologics and Viatris co-developed the products
Biocon Biologics and Viatris co-developed the products
The Akovaz brand and generic market had U.S. sales of approximately US $ 67.5 million MAT for the most recent twelve months ending in August 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Filing marks first protein-based vaccine submitted to MHRA for authorization
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Support from DFC will help produce one billion vaccine doses by the end of 2022
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Subscribe To Our Newsletter & Stay Updated
